China Isotope & Radiation (HKG:1763) Has A Pretty Healthy Balance Sheet

By
Simply Wall St
Published
April 01, 2021
SEHK:1763

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that China Isotope & Radiation Corporation (HKG:1763) does use debt in its business. But is this debt a concern to shareholders?

When Is Debt A Problem?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. If things get really bad, the lenders can take control of the business. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. When we think about a company's use of debt, we first look at cash and debt together.

View our latest analysis for China Isotope & Radiation

How Much Debt Does China Isotope & Radiation Carry?

You can click the graphic below for the historical numbers, but it shows that China Isotope & Radiation had CN¥662.8m of debt in December 2020, down from CN¥788.1m, one year before. However, its balance sheet shows it holds CN¥2.56b in cash, so it actually has CN¥1.89b net cash.

debt-equity-history-analysis
SEHK:1763 Debt to Equity History April 1st 2021

How Strong Is China Isotope & Radiation's Balance Sheet?

Zooming in on the latest balance sheet data, we can see that China Isotope & Radiation had liabilities of CN¥2.77b due within 12 months and liabilities of CN¥907.5m due beyond that. Offsetting these obligations, it had cash of CN¥2.56b as well as receivables valued at CN¥2.37b due within 12 months. So it can boast CN¥1.25b more liquid assets than total liabilities.

This excess liquidity suggests that China Isotope & Radiation is taking a careful approach to debt. Because it has plenty of assets, it is unlikely to have trouble with its lenders. Simply put, the fact that China Isotope & Radiation has more cash than debt is arguably a good indication that it can manage its debt safely.

But the bad news is that China Isotope & Radiation has seen its EBIT plunge 13% in the last twelve months. We think hat kind of performance, if repeated frequently, could well lead to difficulties for the stock. There's no doubt that we learn most about debt from the balance sheet. But ultimately the future profitability of the business will decide if China Isotope & Radiation can strengthen its balance sheet over time. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

Finally, a company can only pay off debt with cold hard cash, not accounting profits. China Isotope & Radiation may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Considering the last three years, China Isotope & Radiation actually recorded a cash outflow, overall. Debt is far more risky for companies with unreliable free cash flow, so shareholders should be hoping that the past expenditure will produce free cash flow in the future.

Summing up

While we empathize with investors who find debt concerning, you should keep in mind that China Isotope & Radiation has net cash of CN¥1.89b, as well as more liquid assets than liabilities. So we don't have any problem with China Isotope & Radiation's use of debt. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. For example, we've discovered 1 warning sign for China Isotope & Radiation that you should be aware of before investing here.

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

Promoted
If you’re looking to trade China Isotope & Radiation, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.


This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.


Simply Wall St character - Warren

Simply Wall St

Simply Wall St is a financial technology startup focused on providing unbiased, high-quality research coverage on every listed company in the world. Our research team consists of equity analysts with a public, market-beating track record. Learn more about the team behind Simply Wall St.